A carregar...
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors
Inhibitors targeting active protein kinases, such as EGFR or ALK, have demonstrated significant efficacy in the treatment of lung cancer. Activating mutations in the MAPK pathway, which includes the enzymes RAS, RAF, MEK, and ERK, result in constitutive signalling, leading to oncogenic cell prolifer...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pioneer Bioscience Publishing Company
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367599/ https://ncbi.nlm.nih.gov/pubmed/25806238 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2013.04.01 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|